Peptide Monograph

SS-31

Elamipretide / Bendavia / MTP-131 (D-Arg-Dmt-Lys-Phe-NH2)

At a Glance

Mechanism of Action

SS-31 (elamipretide) is a synthetic cell-permeable tetrapeptide composed of alternating aromatic and basic amino acids (D-Arg-2',6'-dimethyltyrosine-Lys-Phe-NH2). Its design incorporates the non-natural amino acid 2',6'-dimethyltyrosine (Dmt) and a D-arginine residue, which confer resistance to enzymatic degradation and enable rapid cellular uptake independent of mitochondrial membrane potential.[1]

The defining pharmacological feature of SS-31 is its selective targeting of cardiolipin in the inner mitochondrial membrane. Cardiolipin is a unique diphosphatidylglycerol lipid found almost exclusively in the inner mitochondrial membrane, where it plays essential structural and functional roles in maintaining electron transport chain (ETC) complex organization and cristae architecture. SS-31 binds to cardiolipin through electrostatic and hydrophobic interactions, stabilizing its structure and preventing pathological remodeling.[1][2]

By stabilizing cardiolipin, SS-31 achieves several interconnected effects on mitochondrial function. It optimizes electron transport chain efficiency, improving the coupling between electron transfer and ATP synthesis. This reduces electron leak at complexes I and III, thereby decreasing the production of reactive oxygen species (ROS) at their site of generation rather than scavenging them after formation. This distinguishes SS-31 from conventional antioxidants.[2]

SS-31 also prevents opening of the mitochondrial permeability transition pore (mPTP), a critical event in cell death pathways. By maintaining cardiolipin integrity, SS-31 preserves mitochondrial membrane potential, prevents cytochrome c release, and inhibits the apoptotic cascade. This mechanism underlies its demonstrated cardioprotective and neuroprotective effects in preclinical models.[1]

A remarkable property of SS-31 is its >1,000-fold concentration in mitochondria relative to the cytoplasm within minutes of cellular exposure. This targeted accumulation is driven by the peptide's intrinsic physicochemical properties rather than by mitochondrial membrane potential, allowing it to reach dysfunctional mitochondria that have lost their membrane potential — a key advantage over triphenylphosphonium (TPP+)-based mitochondrial targeting strategies.[2]

Evidence Summary

Preclinical Studies

Szeto et al. established the foundational preclinical evidence for SS-31, demonstrating that the peptide reduced mitochondrial ROS production, prevented mPTP opening, and protected against ischemia-reperfusion injury in cardiac, renal, and neuronal models. In rat models of heart failure, SS-31 improved cardiac function, reduced fibrosis, and preserved mitochondrial ultrastructure.[1]

Birk et al. characterized SS-31's interaction with cardiolipin in detail, demonstrating that the peptide stabilizes cardiolipin-dependent mitochondrial cristae structure and prevents the cardiolipin peroxidation that occurs during oxidative stress. This work established the mechanistic basis for SS-31's protective effects and distinguished it from simple ROS scavengers.[2]

Clinical Trials

The TAZPOWER trial evaluated elamipretide in patients with Barth syndrome, a rare X-linked mitochondrial disease caused by mutations in the tafazzin gene that result in cardiolipin remodeling deficiency. Elamipretide received orphan drug designation for Barth syndrome. The trial showed improvements in the 6-minute walk test and cardiac stroke volume in some patients, though the study had a small sample size.[3]

The MMPOWER trials (MMPOWER-1, MMPOWER-2, MMPOWER-3) investigated elamipretide in primary mitochondrial myopathy. While some patients showed functional improvements, the Phase 3 MMPOWER-3 trial did not meet its primary endpoint of improvement in the 6-minute walk test distance at 24 weeks, though secondary endpoints and subgroup analyses showed signals of benefit.[4]

The ReCLAIM trials investigated elamipretide for dry age-related macular degeneration (AMD), a condition with significant mitochondrial dysfunction in the retinal pigment epithelium. Early results showed improvements in some visual function measures, though the program has had setbacks in meeting primary endpoints.[4]

Additional clinical investigations have explored elamipretide in heart failure with preserved ejection fraction (HFpEF) and renal ischemia-reperfusion injury, with varying results.

Primary Uses (in Research)

Based on the available preclinical and clinical literature, SS-31 has been investigated for the following applications:

• Barth syndrome — Orphan drug designation for this rare mitochondrial cardiomyopathy caused by cardiolipin remodeling deficiency. Clinical trial data shows potential benefit.[3]
• Primary mitochondrial myopathy — MMPOWER trial program targeting exercise intolerance and fatigue in patients with genetically confirmed mitochondrial disease.[4]
• Age-related macular degeneration (dry AMD) — ReCLAIM program investigating subcutaneous elamipretide for geographic atrophy and visual function decline.[4]
• Heart failure — Preclinical and early clinical investigation in heart failure with preserved ejection fraction (HFpEF) and ischemic cardiomyopathy.[1]
• Ischemia-reperfusion injury — Protective effects against cardiac, renal, and cerebral ischemia-reperfusion injury demonstrated in preclinical models.[1][2]
• Aging and age-related mitochondrial decline — Preclinical evidence for reversing age-related mitochondrial dysfunction in skeletal muscle, heart, and kidney.[5]

Contraindications

Standard Protocols

Common Stacks & Synergies

SS-31 is primarily investigated as a standalone agent in clinical trials. In the research and self-experimentation community, the following combinations are sometimes discussed but lack published clinical evidence for combined use:

• SS-31 + CoQ10 (Ubiquinol) — CoQ10 is an endogenous component of the electron transport chain. The rationale is that SS-31 stabilizes the mitochondrial membrane architecture while CoQ10 directly supports electron transport. These mechanisms are theoretically complementary.
• SS-31 + NAD+ precursors (NMN/NR) — NAD+ is essential for mitochondrial oxidative phosphorylation. Combining SS-31's cardiolipin stabilization with NAD+ repletion targets mitochondrial dysfunction from multiple angles.
• SS-31 + MOTS-c — Both peptides target mitochondrial function but through distinct mechanisms (SS-31 via structural cardiolipin stabilization; MOTS-c via AMPK-mediated metabolic reprogramming). The combination is discussed in longevity and biohacking communities.
• SS-31 + PQQ (Pyrroloquinoline quinone) — PQQ promotes mitochondrial biogenesis, potentially complementing SS-31's effects on existing mitochondrial function.

Preparation & Administration

In clinical trials, elamipretide is supplied as a sterile, ready-to-use solution for subcutaneous injection or as a lyophilized powder for IV infusion reconstitution. Research chemical versions are typically supplied as lyophilized powder requiring reconstitution.

Reconstitution (Research Chemical)

For lyophilized research-grade SS-31, reconstitute with bacteriostatic water. The small molecular weight (639.83 Da) and relatively high dosing (milligram range) mean that larger injection volumes may be needed depending on the concentration prepared. For detailed step-by-step reconstitution instructions and a concentration calculator, see the Reconstitution Guide.

Injection

Subcutaneous injections should be administered using a 29–31 gauge insulin syringe. In clinical trials, the abdomen has been the primary injection site. Rotate injection sites to minimize local reactions. For injection technique, site selection, and sterile procedure, see the Injection Safety Guide.

Side Effects & Adverse Events

Across clinical trials (TAZPOWER, MMPOWER, ReCLAIM), elamipretide has demonstrated a favorable safety profile. The most common adverse events were injection-site related and generally mild in severity.[3][4]

Reported adverse events from clinical trials:

• Injection site reactions (erythema, pain, induration, pruritus) — most common, reported in ~15–30% of participants
• Headache
• Nausea (mild to moderate)
• Fatigue
• Dizziness
• Upper respiratory tract infections (comparable to placebo)

No drug-related serious adverse events have been consistently attributed to elamipretide in published clinical trial data. Injection site reactions were the primary reason for dose modifications in some participants.

Drug Interactions

Formal drug-drug interaction studies with elamipretide are limited. The following considerations are based on the peptide's pharmacological properties and clinical trial data:

• Renally cleared medications — As elamipretide is primarily cleared by the kidneys, co-administration with other renally cleared drugs could theoretically affect elimination kinetics, though no clinically significant interactions have been identified in trials.
• Antioxidant supplements — High-dose antioxidant supplements could theoretically interfere with SS-31's mechanism, as the peptide works by optimizing electron transport rather than scavenging ROS. Whether exogenous antioxidants blunt or enhance SS-31's effects is unknown.
• Medications affecting mitochondrial function — Drugs known to impair mitochondrial function (e.g., statins, certain antibiotics, valproic acid, nucleoside reverse transcriptase inhibitors) could theoretically interact with SS-31's mitochondrial-protective mechanism.
• Nephrotoxic agents — Given renal clearance, co-administration with nephrotoxic agents could affect elamipretide elimination.

Storage & Handling

Do not freeze reconstituted solution. Protect from prolonged light exposure. If the solution appears cloudy, discolored, or contains particulate matter, discard the vial. Always use bacteriostatic water (not sterile water) for reconstitution to provide antimicrobial preservation for multi-dose use.

Legal & Regulatory Status

• FDA (United States) — Not approved for any indication. Elamipretide has received orphan drug designation for Barth syndrome and primary mitochondrial myopathy. Multiple IND applications active through Stealth BioTherapeutics.
• Stealth BioTherapeutics — The peptide is being developed by Stealth BioTherapeutics (now part of the Larimar Therapeutics pipeline after corporate restructuring). The clinical development program includes trials in Barth syndrome, mitochondrial myopathy, and dry AMD.
• Research chemical availability — SS-31 is available from research chemical suppliers outside the clinical development pipeline. These products are unregulated and labeled "not for human consumption."
• WADA (World Anti-Doping Agency) — Not specifically listed on the WADA Prohibited List as of 2026, but could potentially fall under S0 ("non-approved substances").
• European Union — Not approved as a medicinal product. Orphan drug designations may apply in some EU member states.

Open Questions

Despite advancing through clinical trials, significant questions remain about SS-31:

• Clinical efficacy — Several Phase 3 trials have failed to meet primary endpoints despite biomarker improvements. Whether the clinical outcome measures (e.g., 6-minute walk test) are sufficiently sensitive to capture SS-31's mitochondrial benefits is debated.
• Patient selection — Mitochondrial diseases are heterogeneous. Identifying which patients are most likely to benefit from SS-31 based on their specific genetic mutation and disease phenotype remains an open challenge.
• Optimal dose and duration — The relationship between dose, mitochondrial biomarker response, and clinical outcomes is not fully characterized. Whether higher or lower doses, or longer treatment durations, would improve outcomes is unclear.
• Long-term safety — The consequences of chronic cardiolipin modulation over years of treatment are unknown. Whether prolonged alteration of mitochondrial membrane dynamics could have unintended effects is an open question.
• Aging applications — Preclinical data supporting SS-31 for age-related mitochondrial decline is compelling, but no clinical trials have been conducted in the general aging population. Whether healthy older adults would benefit remains speculative.
• Research chemical purity — SS-31 available from research chemical suppliers may vary significantly in purity and composition compared to pharmaceutical-grade elamipretide used in clinical trials.

Bibliography

1. Szeto HH. "First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics." Br J Pharmacol. 2014;171(8):2029-50. doi:10.1111/bph.12461. PMID:24117165.
2. Birk AV, Liu S, Soong Y, Mills W, Singh P, Warren JD, Seshan SV, Pardee JD, Szeto HH. "The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin." J Am Soc Nephrol. 2013;24(8):1250-61. doi:10.1681/ASN.2012121216. PMID:23813215.
3. Karaa A, Haas R, Goldstein A, Vockley J, Cohen BH. "A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy." J Cachexia Sarcopenia Muscle. 2020;11(4):909-918. doi:10.1002/jcsm.12559. PMID:32159927.
4. Stealth BioTherapeutics. "Elamipretide clinical development pipeline." Corporate pipeline information accessed via clinical trial registries (ClinicalTrials.gov: NCT03098797, NCT03323749, NCT02693119).
5. Siegel MP, Kruse SE, Percival JM, Goh J, White CC, Hopkins HC, Kavanagh TJ, Szeto HH, Rabinovitch PS, Marcinek DJ. "Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice." Aging Cell. 2013;12(5):763-71. doi:10.1111/acel.12102. PMID:23692570.